QURE uniQure N.V.

50.48
+2.67  (+6%)
Previous Close 47.81
Open 48.97
Price To Book 6.92
Market Cap 2,234,734,809
Shares 44,269,707
Volume 548,514
Short Ratio
Av. Daily Volume 392,653
Stock charts supplied by TradingView

NewsSee all news

  1. uniQure to Participate in Multiple Upcoming Investor Conferences in April

    LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

  2. uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today

  3. uniQure to Participate in Multiple Upcoming Industry Conferences in March

    LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

  4. uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters

    ~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure's Product Portfolio ~ ~ uniQure Receives Option to Acquire Gen-X Business for Use in Gene Therapy ~ LEXINGTON, Mass.

  5. uniQure Announces 2019 Financial Results and Highlights Recent Company Progress

    ~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease Expected to Occur

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to commence 1Q 2020 with imaging and biomarker data due in 2021.
AMT-130
Huntington's disease
Phase 3 top-line data due in 2020.
AMT-061 (HOPE-B)
Hemophilia B
Evaluating partnership opportunities to accelerate completion.
AMT-060
Parkinson’s disease (PD)
Phase 2b one-year data presented at EAHAD February 7, 2020.
AMT-061
Hemophilia B

Latest News

  1. uniQure to Participate in Multiple Upcoming Investor Conferences in April

    LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

  2. uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today

  3. uniQure to Participate in Multiple Upcoming Industry Conferences in March

    LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

  4. uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters

    ~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure's Product Portfolio ~ ~ uniQure Receives Option to Acquire Gen-X Business for Use in Gene Therapy ~ LEXINGTON, Mass.

  5. uniQure Announces 2019 Financial Results and Highlights Recent Company Progress

    ~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease Expected to Occur

  6. uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI's 15th Annual Huntington's Disease Therapeutics Conference

    ~ Up to Two Years of Follow-up in Large Transgenic Huntington's Disease Model Demonstrates Stable mHTT Protein Lowering ~  ~ Novel Preclinical Data Demonstrates Successful Lowering of Pathogenic Exon 1 Fragment ~ ~

  7. uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

    LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,

  8. uniQure to Participate in Multiple Upcoming Industry Conferences in February

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 31, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,

  9. uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington's Disease Supporting Non-Selective HTT-Lowering Approach

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 19, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical

  10. uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

    ~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No Requirement for Immunosuppression in One Year

  11. uniQure to Participate in Multiple Upcoming Industry Conferences in December

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,

  12. uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical

  13. uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,

  14. uniQure to Participate in Multiple Upcoming Industry Conferences in November

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,

  15. uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical

  16. uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress

    ~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~ ~ Achieved Site Initiation and Began Patient Screening for Phase I/II Clinical Study of AMT-130 in Huntington's

  17. uniQure to Participate in Multiple Upcoming Industry Conferences in October

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 27, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,

  18. uniQure Announces Pricing of its Public Offering

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical

  19. uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 03, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical

  20. uniQure to Participate in Multiple Upcoming Industry Conferences in September

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,